ERS International Congress, Milan 2017

Browse by day: Saturday, 09.09.2017 Sunday, 10.09.2017 Monday, 11.09.2017 Tuesday, 12.09.2017 Wednesday, 13.09.2017		Sponsored symposia: Industry Evening Symposium at ERS 2017: “Evolving Concepts in Asthma with Type 2 Inflammation: the Role of Biologics”

Citations should be made in the following way: Authors. Title. Eur Respir J 2017; 50: Suppl. 61, abstract number.

Oral Presentation
Chairs: S. Tiberi (London, United Kingdom), G. Bothamley (London, United Kingdom)

Bedaquiline (BQ)-containing regimen at the programmatic level for MDR-TB: preliminary results S. Borisov (Moscow, Russian Federation)
New and repurposed TB drugs use in children and adolescents with M/XDR-TB A. Skrahina (Minsk region, Belarus)
Eligibility for WHO shorter MDR treatment regimen among foreign-born MDR PTB patients in Singapore C. Chee (Singapore, Singapore)
High rates of resistance to second line drugs are routinely encountered in Mumbai,India for XDR-TB;highlighting the need for new agents. R. Banka (MUMBAI (MAHARASHTRA), India)
The efficacy, safety and tolerability of the short 12-month MDR-TB regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase N. Lytvynenko (Kyiv, Ukraine)
The effect of resection surgery on long-term treatment outcomes of patients with MDR/XDR-TB Y. Batyrshina (Novosibirsk, Russian Federation)
Thoracic surgery may improve outcome for bilateral cavitary multidrug- and extensively drug-resistant TB K. Vladimirov (St Petersburg, Russian Federation), A. Starshinova (ST PETERSBURG, Russian Federation)